DDrare: Database of Drug Development for Rare Diseases

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bromocriptine; Cabergoline; Clomiphene; Clomiphene citrate; Curcumin; Dexamethasone; Dopamine; Dopamine Agonists; Dopamine agonist treatment; Drug treatment; Gamma-secretase/Notch signalling pathway inhibitor RO4929097; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; HCQ/CQ and CAB combined treatment; Lapatinib; Other: Surgery; Other: diagnostic laboratory biomarker analysis; Other: pharmacological study; PASIREOTIDE; Pasireotide; Procedure: Endoscopic trans-sphenoidal adenoma resection; Procedure: transsphenoidal surgery treatment; Ropinirole; SOM230; SOMATROPIN; Somatropin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03038308 (ClinicalTrials.gov)	September 16, 2016	30/1/2017	Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole	Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability	Hyperprolactinemia;Prolactinoma	Drug: Ropinirole	Columbia University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Active, not recruiting	18 Years	70 Years	All	23	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03038308
(ClinicalTrials.gov)

September 16, 2016

30/1/2017

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability

Hyperprolactinemia;Prolactinoma

Drug: Ropinirole

Columbia University

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

18 Years

70 Years

All

Phase 1;Phase 2

United States